Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Lung Disease Therapeutics Market Outlook

The global lung disease therapeutics market is likely to garner a market value of US$ 83,398.60 million in 2023 and is expected to accumulate a market value of US$ 152,369.26 million by registering a CAGR of 6.2% in the forecast period.

Growth of the lung disease therapeutics market can be attributed to increasing air pollution and the rising prevalence of COPD. The market for lung disease therapeutics registered a CAGR of 3.9% in the historical period 2018 to 2022.

Lungs are the complex human organ that brings in oxygen and expels carbon dioxide by expanding and relaxing continuously. Lung disease is one of the most common medical conditions globally. Lung disease is very severe and is highly responsible for increasing mortality around the globe. Lung disease leads to uneasiness and complications in respiration.

Some key lung diseases are COPD, asthma, bronchopulmonary dysplasia, and pulmonary fibrosis. Basically, there are two types of treatment for lung disease viz drug treatment and oxygen therapy. Drug treatment is most preferred by physicians as well as patients owing to its instant effect. Oxygen therapy is provided to COPD patients through ventilators and concentrators for long-term care.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Which are some Prominent Drivers Spearheading Lung Disease Therapeutics Market Growth?

The rising prevalence of COPD and asthma are the primary factors driving the market growth. The change in lifestyle of people and increase in numbers of smokers globally is likely to propel the growth of lung disease therapeutics sector. Besides, the rising geriatric population suffering from various lung diseases spur the growth of the market.

Furthermore, advancement in technology and increasing research and development leads to availability of more efficient drug therapeutics which is likely to boost the market growth.

The market is expected to show exponential growth over the forecast period. The lung disease therapeutics industry is classified on the basis of disease type, treatment type and distribution channel. By disease type, COPD segment is expected to dominate the market value of lung disease therapeutics sector.

Drug treatment is expected to be the most lucrative segment for lung disease therapeutics business by treatment type. Among all distribution channels, retail pharmacies are expected to show faster growth than other segments.

Attributes Details
Lung Disease Therapeutics Market CAGR (2023 to 2033) 6.2%
Lung Disease Therapeutics Market Size (2023) US$ 83,398.60 million
Lung Disease Therapeutics Market Size (2033) US$ 152,369.26 million

What are the Challenges Faced By The Lung Disease Therapeutics Industry?

The Cost Associated with the Treatment of Lung Diseases Impede the Growth of the Market

Although the lung disease therapeutics market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease is likely to restrain the growth of this market to some extent.

Some side effects after consumption of anti-inflammatory drugs also hinder the growth of the lung disease therapeutics sector. All these factors are expected to derail the progress of the market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of the Market

Lung Disease Therapeutics Market:

Attributes Lung Disease Therapeutics Market
CAGR (2023 to 2033) 6.2%
Market Value (2033) US$ 152,369.26 million
Growth Factor Rising prevalence of asthma
Opportunity Advancement in technology
Key Trends Surging air pollution

Compression Therapy Market:

Attributes Compression Therapy Market
CAGR (2023 to 2033) 5.4%
Market Value (2033) US$ 4,840 million
Growth Factor Growing incidence of venous ulcers
Opportunity Development of patient -centric products
Key Trends Applications in promoting mental health

Negative Pressure Wound therapy Market:

Attributes Negative Pressure Wound therapy Market
CAGR (2023 to 2033) 5.2%
Market Value (2033) US$ 6,520 million
Growth Factor Surging prevalence of chronic wounds
Opportunity Growing awareness about advanced wound treatment
Key Trends Rising preference of cost-effective treatment

Region Analysis

Countries Market share (2022)
United States 32.2%
Germany 5.9%
Japan 3.7%

Why Is North America Emerging As An Opportunistic Lung Disease Therapeutics Industry?

North America is expected to have the maximum market share of the lung disease therapeutics market due to the high number of people suffering from COPD and asthma in the United States After North America. In addition, technologically advanced healthcare facilities are contributing to the growth of the market.

Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, North America possessed 35.3% market share in 2022.

In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of the market. According to the American Lung Association, COPD is the third most common cause of death in the country.

How is Europe Likely to Contribute to Lung Disease Therapeutics Industry Growth?

Rising healthcare infrastructure and favorable medical insurance are responsible for the high growth of the market in Western Europe. Rising pollution and climate change in the European region lead to robust market growth.

Moreover, government initiatives to spread awareness regarding regular lung check-ups is escalating the demand for lung disease therapeutics. Thus, Europe held a 28.7% market share in 2022. The region's market is being driven by an increase in the prevalence of chronic disease and Asthma is the most common issue among children.

A number of technological advancements in respiratory diagnostic testing have paved the way for the market's expansion, including the use of artificial intelligence and the Internet of things (IoT), among other things.

Does the Asia Pacific Emerge As An Attractive Lung Disease Therapeutics Industry?

Countries Details
China 9.2%
India 7.5%

The Asia Pacific is expected to remain at the forefront by generating the leading lung diseases therapeutics market share in the upcoming years. The presence of numerous leading companies in the region is anticipated to drive the regional market. The rising aging population prone to lung diseases across developing countries, such as India and China is likely to propel the demand for lung disease therapeutics in the Asia Pacific.

The high penetration rate of state-of-the-art devices and the presence of a well-established healthcare system across the Asia Pacific are a couple of other factors that foster the market. For instance, In August 2022- Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.

Innovent is a leading biopharmaceutical company with strong clinical development capabilities and a broad commercial footprint in China.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-ups For Lung Disease Therapeutics Market

Key start-up players in lung disease therapeutics are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat and ReAlta Life Sciences.

  • Altavant Sciences, a key start-up in the lung disease therapeutics market, is developing small molecule inhibitors as respiratory drugs for the treatment of COPD.

Market Competition

Examples of some of the market participants in the lung disease therapeutics sector identified across the value chain include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, Roche, Teva Pharmaceuticals, Astellas Pharma, Asmacure Ltée, Dr. Reddy’s Laboratories Ltd.

Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Sanofi account for considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.

  • In June 2022, AstraZeneca announced that the company’s Imfinzi exhibited positive high-level results in resectable non-small cell lung cancer.
  • In February 2020 – Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorization for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.
    • In September, the United States Food and Drug Administration (FDA) approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with SSc-ILD.
    • Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan, and Brazil.

Key Players

Key Segments

By Disease Type:

  • COPD
  • Chronic Bronchitis
  • Emphysema
  • Bronchopulmonary dysplasia
  • Pulmonary Fibrosis
  • Asthma
  • Other Lung Disease Therapeutics

By Treatment Type:

  • Drugs
    • Diuretics
    • Steroids
  • Bronchodilators
  • Antibiotics
  • Anti-inflammatory Agents
  • Oxygen Therapy
  • Other Treatment Types

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies and E-commerce
  • Drugstores
  • Other Distribution Channels

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Projected Size of the Lung Disease Therapeutic Market by 2033?

The global market size is to reach US$ 152,369.26 million by 2033.

Which Region Holds High Lucrativeness?

North America is projected to emerge as a lucrative market.

What is the Growth Potential of the Lung Disease Therapeutic Market?

The growth potential of the global market is 6.2% in 2023.

What Limits the Growth Potential of the Market?

The rising numerous obstacles is likely to limit market growth.

What is China's Expected Share in 2023?

China is likely to secure a significant CAGR of 9.2% in 2023.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033

        5.3.1. COPD

        5.3.2. Chronic Bronchitis

        5.3.3. Emphysema

        5.3.4. Bronchopulmonary Dysplasia

        5.3.5. Pulmonary Fibrosis

        5.3.6. Asthma

        5.3.7. Other Lung Disease Therapeutics

    5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        6.3.1. Drugs

            6.3.1.1. Diuretics

            6.3.1.2. Steroids

        6.3.2. Bronchodilators

        6.3.3. Antibiotics

        6.3.4. Anti-inflammatory Agents

        6.3.5. Oxygen Therapy

        6.3.6. Other Treatment Types

    6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies and E-commerce

        7.3.4. Drugstores

        7.3.5. Other Distribution Channels

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Disease Type

        9.2.3. By Treatment Type

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease Type

        9.3.3. By Treatment Type

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Disease Type

        10.2.3. By Treatment Type

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Type

        10.3.3. By Treatment Type

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Disease Type

        11.2.3. By Treatment Type

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Type

        11.3.3. By Treatment Type

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Disease Type

        12.2.3. By Treatment Type

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Type

        12.3.3. By Treatment Type

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Disease Type

        13.2.3. By Treatment Type

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Type

        13.3.3. By Treatment Type

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Disease Type

        14.2.3. By Treatment Type

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Disease Type

        14.3.3. By Treatment Type

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Disease Type

        15.2.3. By Treatment Type

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Disease Type

        15.3.3. By Treatment Type

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Disease Type

            16.1.2.2. By Treatment Type

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Disease Type

            16.2.2.2. By Treatment Type

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Disease Type

            16.3.2.2. By Treatment Type

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Disease Type

            16.4.2.2. By Treatment Type

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Disease Type

            16.5.2.2. By Treatment Type

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Disease Type

            16.6.2.2. By Treatment Type

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Disease Type

            16.7.2.2. By Treatment Type

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Disease Type

            16.8.2.2. By Treatment Type

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Disease Type

            16.9.2.2. By Treatment Type

            16.9.2.3. By Distribution Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Disease Type

            16.10.2.2. By Treatment Type

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Disease Type

            16.11.2.2. By Treatment Type

            16.11.2.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Disease Type

            16.12.2.2. By Treatment Type

            16.12.2.3. By Distribution Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Disease Type

            16.13.2.2. By Treatment Type

            16.13.2.3. By Distribution Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Disease Type

            16.14.2.2. By Treatment Type

            16.14.2.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Disease Type

            16.15.2.2. By Treatment Type

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Disease Type

            16.16.2.2. By Treatment Type

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Disease Type

            16.17.2.2. By Treatment Type

            16.17.2.3. By Distribution Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Disease Type

            16.18.2.2. By Treatment Type

            16.18.2.3. By Distribution Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Disease Type

            16.19.2.2. By Treatment Type

            16.19.2.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Disease Type

            16.20.2.2. By Treatment Type

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Disease Type

            16.21.2.2. By Treatment Type

            16.21.2.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Disease Type

            16.22.2.2. By Treatment Type

            16.22.2.3. By Distribution Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Disease Type

            16.23.2.2. By Treatment Type

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Disease Type

        17.3.3. By Treatment Type

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. GlaxoSmithKline

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Boehringer Ingelheim

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. AstraZeneca

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Novartis

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Sanofi

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Roche

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Teva Pharmaceuticals

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Astellas Pharma

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Asmacure Ltée

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Dr. Reddy’s Laboratories Ltd.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Western Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 15: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 20: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 27: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 28: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 17: Global Market Attractiveness by Disease Type, 2023 to 2033

Figure 18: Global Market Attractiveness by Treatment Type, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 37: North America Market Attractiveness by Disease Type, 2023 to 2033

Figure 38: North America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Disease Type, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Western Europe Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 62: Western Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 63: Western Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Western Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 71: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 74: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 77: Western Europe Market Attractiveness by Disease Type, 2023 to 2033

Figure 78: Western Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 79: Western Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Eastern Europe Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 82: Eastern Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 83: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 97: Eastern Europe Market Attractiveness by Disease Type, 2023 to 2033

Figure 98: Eastern Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 99: Eastern Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: South Asia and Pacific Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 102: South Asia and Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 103: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 117: South Asia and Pacific Market Attractiveness by Disease Type, 2023 to 2033

Figure 118: South Asia and Pacific Market Attractiveness by Treatment Type, 2023 to 2033

Figure 119: South Asia and Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 121: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 122: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 123: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 124: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 129: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 131: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 134: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 135: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 137: East Asia Market Attractiveness by Disease Type, 2023 to 2033

Figure 138: East Asia Market Attractiveness by Treatment Type, 2023 to 2033

Figure 139: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 140: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 141: Middle East and Africa Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 142: Middle East and Africa Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 143: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 157: Middle East and Africa Market Attractiveness by Disease Type, 2023 to 2033

Figure 158: Middle East and Africa Market Attractiveness by Treatment Type, 2023 to 2033

Figure 159: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 160: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Lung Cancer Surgery Market

Published : June 2022

Healthcare

Lung Cancer Therapeutics Market

Published : June 2022

Explore Healthcare Insights

View Reports

Lung Disease Therapeutics Market